Clinical trial
Biological Therapy and Temozolomide in Treating Patients With Metastatic…
NCT00016055 · St. Luke's Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00016055 |
|---|---|
| Title | Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma |
| Official title | Interleukin 12-Primed Activated T Cells As Therapy For Patients With Metastatic Melanoma (Phase I) |
| Lead sponsor | St. Luke's Medical Center, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | lymphokine-activated killer cells, temozolomide |
| Enrollment | 18 |
| Start date | Nov 1, 2000 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: